Evidence map›Paper›PMID 29785104›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2018

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.

Alejandro Casas, Maria Montes de Oca, Ana Mb Menezes, Fernando C Wehrmeister, Maria Victorina Lopez Varela, Laura Mendoza, Larissa Ramírez, Marc Miravitlles

Erratum issuedOpen access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023
    Review
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study.International journal of chronic obstructive pulmonary disease · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 7 countries.

Alejandro CasasFundación Neumológica Colombiana, Universidad del Rosario, Bogotá, Colombia.
Maria Montes de OcaUniversidad Central de Venezuela, Caracas, Venezuela.
Ana Mb MenezesFederal University of Pelotas, Pelotas, Brazil.
Fernando C WehrmeisterFederal University of Pelotas, Pelotas, Brazil.
Maria Victorina Lopez VarelaUniversidad de la República, Montevideo, Uruguay.
Laura MendozaHospital Clínico Universidad de Chile, Santiago de Chile, Chile.
Larissa RamírezAstraZeneca, San José, Costa Rica.
Marc MiravitllesDepartment of Pneumology, Hospital Universitari Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
Universidad de la República de Uruguay · UYUniversidade Federal de Pelotas · BRAstraZeneca (Poland) · PLCentral University of Venezuela · VECentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESFundación Neumológica Colombiana · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region. Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other. Results: In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsCross-Sectional StudiesDrug PrescriptionsDrug Therapy, CombinationDrug Utilization ReviewFemaleHealthcare DisparitiesHealth Care SurveysHumansLatin AmericaLungMaleAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic AntagonistsadherenceCOPDinhaled therapyLatin America

Identifiers

PMID29785104
PMCPMC5955011
OpenAlexW2800317042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.